COVID-19 | BioTuesdays

Developments

U of Maryland School of Medicine lab approved as development site for RNA Disease Diagnostics COVID-19 test

The FDA registered the laboratory of Dipanjan Pan, Ph.D., at the University of Maryland School of Medicine, as an approved laboratory development site for RNA Disease Diagnostics’ (RNADD) Antisense COVID-19 molecular...

June 3, 2021

Developments

iBio posts positive COVID-19 vaccine toxicology study results; announces next-generation COVID-19 vaccine program

iBio (NYSE American:IBIO) updated its IBIO-201 program and reported progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201...

May 7, 2021

Developments

RNA Disease Diagnostics stepwise protocol for molecular diagnosis of COVID-19 published in Nature Protocols

RNA Disease Diagnostics’ stepwise protocol for an RNA-extraction-free nano-amplified colorimetric test for COVID-19 was published in Nature Protocols. The test uses a unique dual-pronged molecular sensing approach that...

May 6, 2021

Markets

Maxim starts MediciNova at buy; PT $15

Maxim Group launched coverage of MediciNova (NASDAQ:MNOV) with a “buy” rating and $15 price target. The stock closed at $5.68 on March 9. MediciNova is developing MN-166 for neurodegenerative diseases, glioblastoma...

March 10, 2021

Developments

Soricimed approach to COVID-19 being validated by other researchers

Researchers at Rush University Medical Center in Chicago are developing a new peptide treatment to prevent COVID-19 symptoms that supports the approach being taken by closely-held Soricimed Biopharma. The peptide...

January 25, 2021

Developments

aTyr Pharma posts positive topline results from Phase 2 COVID-19 study

aTyr Pharma (NASDAQ:LIFE) announced positive topline results from its Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do...

January 5, 2021

Developments

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

The FDA accepted an IND application from Hepion Pharmaceuticals (NASDAQ:HEPA) for the use of CRV431, a novel cyclophilin inhibitor, for the treatment of COVID-19. Hepion is developing CRV431 as part of its artificial...

December 22, 2020

Developments

Soricimed to investigate SOR-C13 to treat COVID-19

Closely-held Soricimed Biopharma, benefiting from funding support from the National Research Council of Canada Industrial Research Assistance Program, will investigate the potential therapeutic role its cancer drug...

December 17, 2020

Developments

Capricor initiates dosing in Phase 2 COVID-19 trial

Capricor Therapeutics (NASDAQ:CAPR) dosed the first two patients in its Phase 2 trial evaluating CAP-1002 for the treatment of severe COVID-19. CAP-1002 is an intravenously delivered allogeneic cardiac cell therapy...

November 24, 2020

Developments

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen (NASDAQ:HGEN) reported positive interim results from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients. Lenzilumab is an antibody that targets granulocyte-macrophage colony-stimulating...

November 6, 2020

Developments

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

Humanigen (NASDAQ:HGEN) reported that the National Institutes of Health (NIH) has dosed the first hospitalized COVID-19 patient with lenzilumab. Lenzilumab is an antibody that targets granulocyte-macrophage colony...

October 29, 2020

Developments

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Hepion Pharmaceuticals (NASDAQ:HEPA) will present virtually at the Roth Capital “therapeutic approaches for COVID-19” event taking place on Oct. 28 from 9:00 am to 1:20 pm ET; and at the B. Riley Securities...

October 26, 2020

Developments

PhaseBio discontinues Phase 2 COVID-19 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) discontinued its Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of vasoactive intestinal peptide...

October 23, 2020

Developments

Rigel Pharma enrolls first patients in Phase 2 COVID-19 trial

Rigel Pharmaceuticals (NASDAQ:RIGL) enrolled the first patients in its Phase 2 trial evaluating fostamatinib for the treatment of hospitalized COVID-19 patients. The study is sponsored by the NIH’s National Heart, Lung...

October 9, 2020

Features

Monopar Therapeutics readies two key clinical trials in fourth quarter

Monopar Therapeutics (NASDAQ:MNPR), which focuses on developing cancer therapies and treatments for cancer-related adverse events, is on track for two important clinical trials with its lead drug candidates, Validive...

October 6, 2020

Developments

Enlivex posts positive COVID-19 results in severe/critical patients

Enlivex Therapeutics (NASDAQ:ENLV) reported positive topline results of an investigator-initiated clinical trial of Allocetra in five COVID-19 patients, three of which were in severe condition and two in critical...

October 1, 2020

Features

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...

September 29, 2020

Developments

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 demonstrated positive activity against SARS-CoV-2 in a preclinical study conducted at the National Institute of Allergy and Infectious Diseases (NIAID). Conducted under...

September 17, 2020

Features

BioCardia developing autologous and allogenic cardiovascular cell therapies

BioCardia (NASDAQ:BCDA) is developing two late-stage clinical autologous cell therapies, known as CardiAMP, for ischemic heart failure and chronic myocardial ischemia, a neurokinin 1 receptor positive (NK1R+) allogenic...

September 15, 2020

Developments

iBio featured on ABC affiliate

KXXV, an ABC affiliate in Bryan, Texas, published an article on iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates. The company recently reported that it has selected IBIO-201 as its leading candidate for...

September 11, 2020

Developments

Hepion CRV431 featured on The Bio Report podcast

The Bio Report podcast featured Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 for the treatment of non-alcoholic steatohepatitis (NASH), and potentially, COVID-19. “We’ve kicked off our Phase 2 trial in NASH...

September 11, 2020

Developments

iBio selects IBIO-201 as its leading COVID-19 vaccine candidate

iBio (NYSE AMERICAN:IBIO) selected IBIO-201 as its leading candidate for the prevention of SARS-CoV-2 infection. iBio previously reported that both of its COVID-19 vaccine candidates, IBIO-200 and IBIO-201, in...

September 9, 2020

U of Maryland School of Medicine lab approved as development site for RNA Disease Diagnostics COVID-19 test

iBio posts positive COVID-19 vaccine toxicology study results; announces next-generation COVID-19 vaccine program

RNA Disease Diagnostics stepwise protocol for molecular diagnosis of COVID-19 published in Nature Protocols

Maxim starts MediciNova at buy; PT $15

Soricimed approach to COVID-19 being validated by other researchers

aTyr Pharma posts positive topline results from Phase 2 COVID-19 study

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

Soricimed to investigate SOR-C13 to treat COVID-19

Capricor initiates dosing in Phase 2 COVID-19 trial

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

PhaseBio discontinues Phase 2 COVID-19 trial

Rigel Pharma enrolls first patients in Phase 2 COVID-19 trial

Monopar Therapeutics readies two key clinical trials in fourth quarter

Enlivex posts positive COVID-19 results in severe/critical patients

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

BioCardia developing autologous and allogenic cardiovascular cell therapies

iBio featured on ABC affiliate

Hepion CRV431 featured on The Bio Report podcast

iBio selects IBIO-201 as its leading COVID-19 vaccine candidate

General

More